The global Animal Biotechnology Market size occupied USD 24.8 Billion in 2022 and is estimated to arrive at a size of around USD 57.9 Billion by 2032 rising with a CAGR of 8.9% during the forecasted years, as reported by Acumen Research & Consulting
Several factors are driving up demand in the animal biotechnology business. The expanding worldwide population is one of the key drivers of demand, which has led to an increase in demand for animal-based food items. This has resulted in a demand for efficient and sustainable livestock production, which can be met by using modern animal biotechnology products and technologies.
The growing emphasis on animal welfare is another aspect boosting demand in the animal biotechnology business. Consumers are becoming more conscious of the ethical and environmental aspects of animal husbandry, which has resulted in an increase in demand for products produced using sustainable and humane practices. Animal biotechnology can contribute to better animal welfare by developing diagnostic tests, vaccinations, and other items that prevent and treat animal diseases.
The animal biotechnology business is also seeing growth as a result of the growing need for disease prevention and control. Animal illnesses can have a large influence on livestock output and result in major economic losses. Animal biotechnology develops diagnostic tests and vaccines to assist prevent disease transmission, as well as pharmaceuticals to treat animal ailments, resulting in enhanced animal health and productivity.
Animal Biotechnology Market Statistics
Request for a sample of this premium research report@ https://www.acumenresearchandconsulting.com/request-sample/3172
Animal Biotechnology Market Dynamics
Advancements in Genetic Engineering and Cloning Techniques Fuels the Animal Biotechnology Market Value
Advances in genetic engineering and cloning techniques are fueling the growth of the animal biotechnology business. Techniques for genetic engineering allow for the manipulation of an animal's genetic material to introduce desirable qualities or eliminate undesirable ones. This has resulted in the creation of genetically engineered animals that are more disease resistant, produce larger yields, and have other desired characteristics. Animal models for study and medication development are also created using genetic engineering techniques.
Cloning procedures like somatic cell nuclear transfer (SCNT) enable the creation of genetically identical animals. This has important consequences for animal breeding since it enables the creation of animals with desirable features such as disease resistance or increased productivity. Cloning is also utilized to create transgenic animals that have been genetically engineered to produce useful products such as human proteins.
Advances in genetic engineering and cloning techniques are also paving the way for the creation of new and improved animal biotechnology products and services. CRISPR/Cas9 gene editing tools, for example, allow for precise manipulation of an animal's DNA, potentially leading to the development of novel diagnostic tests, vaccinations, and medications.
Development of Novel Therapies and Vaccines For Animal Diseases Will Generate Surplus Animal Biotechnology Market Opportunities
The development of innovative medicines and vaccines for animal diseases is a primary driver of the animal biotechnology industry's growth. Animal illnesses can have a large influence on livestock output and result in major economic losses. Novel medicines and vaccinations can aid in the prevention and treatment of animal diseases, resulting in better animal health and productivity.
Biotechnology advances are enabling the creation of novel medicines and vaccinations for animal ailments. Recombinant DNA technology, for example, is utilized to create vaccinations that are both safer and more effective than standard immunizations. CRISPR/Cas9 gene editing tools are also being utilized to explore innovative therapeutics for genetic abnormalities in animals.
Another growing topic in animal biotechnology is the use of monoclonal antibodies. Monoclonal antibodies are highly specific and can be utilized to specifically target and cure diseases in animals. These antibodies are created utilizing hybridoma technology, which combines antibody-producing cells with cancer cells to form a hybrid cell line capable of producing enormous amounts of monoclonal antibodies.
The development of novel medicines and vaccines for animal diseases is also resulting in the formation of new animal biotechnology firms and collaborations. Animal health companies are collaborating with pharmaceutical companies to create and market novel animal healthcare products and services.
Animal Biotechnology Market Segmentation
The global market has been categorized into product type, application, animal type, end-use, and region.
Animal Biotechnology Market Share
As per the animal biotechnology industry analysis, the vaccines sub-segment is leading the segment with the utmost market share in 2022. In addition to that, diagnostic tests are another sub-segment that has a significant market share.
Based on application, the diagnosis of animal disease sub-segment gathered the utmost market share and is expected to do so in the coming years. Furthermore, the animal preventive care sub-segment accounted for the second-largest market share in 2022.
The livestock animal type occupied the largest animal biotechnology market share, whereas the companion sub-segment is expected to gain a significant growth rate from 2023 to 2032.
According to the animal biotechnology market forecast, veterinary hospitals & clinics are likely to occupy a noteworthy share from 2023 to 2032. Other end-use are also expected to perform well in the coming years.
Animal Biotechnology Market Regional Outlook
North America and Europe are the major markets for animal biotechnology, with well-established animal healthcare sectors and a high degree of knowledge about animal health. These areas contain a high concentration of companion and livestock animals, as well as several of the leading animal biotechnology companies. The United States, which has a well-developed animal healthcare industry and a big number of research organizations and universities active in animal biotechnology research, is the primary driver of the North American market. Germany, France, and the United Kingdom dominate the European market.
The Asia-Pacific region is predicted to have the quickest development in the animal biotechnology market, owing to rising demand for animal products and a greater emphasis in the region on animal health and welfare. Because of their vast livestock populations and increased investment in animal healthcare research and development, countries such as China, Japan, and India are likely to fuel the growth of the animal biotechnology market in the area.
Latin America, the Middle East, and Africa are also likely to see considerable expansion in the animal biotechnology market, owing to rising demand for animal healthcare products and services and a growing livestock population in these regions.
Animal Biotechnology Market Players
Some prominent animal biotechnology companies covered in the industry include Biogénesis Bagó, Boehringer Ingelheim International GmbH, Elanco, Heska Corporation, HESTER BIOSCIENCES LIMITED, Idexx Laboratories, Indian Immunologicals Ltd., Kareo, Inc., Merck & Co., Inc., NXGN Management, LLC, Virbac, and Zoetis.
In March 2021, Boehringer Ingelheim has introduced a new swine vaccination called Ingelvac MycoFLEX. Mycoplasma hyopneumoniae, bacteria that can cause respiratory illness in pigs, is the target of the vaccine.
In December 2020, Zoetis announced the acquisition of Performance Livestock Analytics, a startup that provides livestock producers with data analytics and decision-making tools. Zoetis' position in the animal health sector is likely to improve as a result of the acquisition.
Click here to buy the Premium Market Research report https://www.acumenresearchandconsulting.com/buy-now/0/3172
Receive our personalized services and customization by clicking here https://www.acumenresearchandconsulting.com/request-customization/3172
Mr. Frank Wilson
Acumen Research and Consulting